The main antiviral drug-cyclodextrin interactions, changes in physicochemical and physiological properties of the most commonly used virucides are summarized. The potential complexation of antiviral molecules against the SARS-Cov2 also pointed out the lack of detailed information in designing effective and general medicines against viral infections. The principal problem of the current molecules is the 3D structures of the currently active compounds. Improving the solubility or bioavailability of antiviral molecules is possible, however, there is no universal solution, and the complexation experiments dominantly use the already approved cyclodextrin derivatives. This review discusses the basic properties of the different cyclodextrin derivatives, their potential in antiviral formulations, and the prevention and treatment of viral infections. The biologically active new cyclodextrin derivatives are also discussed.

Cyclodextrins in the antiviral therapy

Jicsinszky L.
First
;
Martina K.;Cravotto G.
Last
2021-01-01

Abstract

The main antiviral drug-cyclodextrin interactions, changes in physicochemical and physiological properties of the most commonly used virucides are summarized. The potential complexation of antiviral molecules against the SARS-Cov2 also pointed out the lack of detailed information in designing effective and general medicines against viral infections. The principal problem of the current molecules is the 3D structures of the currently active compounds. Improving the solubility or bioavailability of antiviral molecules is possible, however, there is no universal solution, and the complexation experiments dominantly use the already approved cyclodextrin derivatives. This review discusses the basic properties of the different cyclodextrin derivatives, their potential in antiviral formulations, and the prevention and treatment of viral infections. The biologically active new cyclodextrin derivatives are also discussed.
2021
64
102589
102607
https://reader.elsevier.com/reader/sd/pii/S1773224721002690?token=BE45B763A5DB466D4B178AC240EA9F26983F81A55A5A50F87551281AC4B8314F8A8219A8A9B432FBAAAB5AAF74887695&originRegion=eu-west-1&originCreation=20210728080138
(2-hydroxy)propyl cyclodextrin; Covid-19; Favipiravir; Fenofibrate; Remdesivir; Sulfobutyl cyclodextrin
Jicsinszky L.; Martina K.; Cravotto G.
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1773224721002690-main.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 6.03 MB
Formato Adobe PDF
6.03 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1795189
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 26
social impact